Case Studies
Real work with PE funds, medical device companies, and healthcare organizations across Europe. Anonymized for confidentiality, these are examples of the kind of challenges we solve.
Results include outcomes delivered both in BHAG client engagements and in the founder's prior executive leadership roles.
Acquisition Target Screening for Strategic Buyer
A mid-sized MedTech company pursuing a bolt-on acquisition strategy needed to rapidly evaluate 25+ target opportunities in the orthopedic space across Germany and Central Europe. Internal resources were stretched; the corporate development team lacked deep market intelligence and risk assessment capability.
AI Due Diligence for Digital Health Acquisition
A PE fund was evaluating a EUR 120M acquisition of a digital health platform with AI-enabled diagnostic capabilities. Traditional commercial DD would miss critical questions: Was the AI clinically validated? Was the data strategy defensible? Could the technology actually scale commercially? Fund needed independent assessment before proceeding.
Buy & Build Commercial Integration for PE Platform
A PE fund had acquired a EUR 150M wound care platform and planned 4-5 bolt-on acquisitions over 3 years. Commercial integration of the first two acquisitions (EUR 45M combined) was creating value destruction: overlapping channels, customer confusion, management distraction. Fund needed a systematic approach to commercial integration to capture value synergies.
Exit Readiness Program for PE-Backed Cardiology Portfolio
A PE-backed cardiology device company was 15 months away from planned exit and needed to strengthen commercial fundamentals and build a compelling growth narrative. Initial valuation expectations exceeded multiples the market was paying for comparable companies. Management needed a roadmap to close the valuation gap.
Interim Country Manager for MedTech Distributor Transformation
Following a EUR 130M+ acquisition, a major MedTech distribution company needed experienced interim leadership to manage the commercial integration in Sweden. The business faced declining margins, customer attrition, and organizational uncertainty among the 150-person sales and operations team.
EMEA Launch Strategy for IoT-Enabled Medical Device
A US-based MedTech company had developed an IoT-enabled monitoring device with strong clinical evidence but no commercial presence in Europe. They needed a comprehensive EMEA launch strategy that addressed regulatory, reimbursement, and go-to-market challenges simultaneously.
Market Expansion Strategy for Urology Device Maker
A Swedish urology device company was profitable in Nordics (EUR 25M revenue) but lacked commercial infrastructure in larger, more complex markets. Expansion into Germany and Benelux required understanding hospital procurement, competitive dynamics, and channel models. Company needed market entry strategy before deploying capital and management bandwidth.
Nordic Market Entry for Surgical Device Company
A European surgical consumables company sought to establish a direct commercial presence in the Nordic market, replacing an underperforming distributor network that had delivered flat revenue for three consecutive years.
Commercial Due Diligence for PE Fund
A mid-market PE fund was evaluating the acquisition of an EUR 80M wound care portfolio from a larger MedTech corporation. The fund needed an independent commercial assessment to validate revenue sustainability, competitive positioning, and growth potential before proceeding with the transaction.
Portfolio Value Creation Program for PE-Backed Orthopedics Company
A PE-backed orthopedics platform company (EUR 200M revenue) was underperforming sponsor return expectations. Market share was stable but pricing power was limited, margins were declining, and geographic expansion plans were delayed. PE sponsor needed a structured approach to capturing commercial value across the portfolio.
Post-Merger Commercial Integration of EUR 130M Acquisition
A global MedTech company had completed the acquisition of a regional competitor valued at EUR 130M. The commercial integration across Northern European markets was behind schedule, with conflicting channel strategies, customer confusion, and declining sales team morale.
Vendor Due Diligence for Diagnostic Device Exit
A UK-based diagnostics company was preparing for sale and needed to strengthen its commercial story before the buyer process. Management wanted to address buyer concerns proactively: customer concentration risk, competitive positioning in a consolidating market, and reimbursement sustainability post-IVD Regulation.